{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027270","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2026-06-04T20:10:29+00:00","discovered_at":"2026-06-04T20:11:00.255562+00:00","generated_at":"2026-06-04T20:42:58.516211+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Azitra adjourns 2026 annual meeting; only 17% of shares voted, needs 33.3% quorum","bullets":["Meeting reconvened to June 15, 2026 at 11:00 a.m. ET; record date remains April 24, 2026.","Proxies received represented approx. 17% of outstanding shares; quorum requires 33⅓%.","No changes to proposals; stockholders can vote by mail, Internet, or phone until June 15 at 10:59 a.m. ET.","Company is a clinical-stage biopharma focused on precision dermatology; lead program ATR-12 for Netherton syndrome."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027270","json":"https://secwatch.observer/filing/0001493152-26-027270.json","markdown":"https://secwatch.observer/filing/0001493152-26-027270.md","text":"https://secwatch.observer/filing/0001493152-26-027270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226027270/0001493152-26-027270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000149315226027270/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:42:58.516211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}